or Try an Advanced Search...

    Technical Analysis for AKBA - Akebia Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 1.40 0.00% 0.00
    AKBA closed unchanged on Wednesday, May 8, 2024, on 50 percent of normal volume.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Up
    Historical AKBA trend table...
    Date Alert Name Type % Chg
    20 DMA Support Bullish 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    50 DMA Resistance Bearish 0.00%
    Bearish Engulfing Bearish 0.00%
    20 DMA Support Bullish 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    Earnings Movers Other 0.00%
    BB Squeeze + Upper Band Touch Range Contraction 0.00%
    BB Squeeze Started Range Contraction 0.00%
    Outside Day Range Expansion 0.00%
    Older End-of-Day Signals for AKBA ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 11 hours ago
    10 DMA Support about 13 hours ago
    Fell Below 10 DMA about 13 hours ago
    60 Minute Opening Range Breakdown about 14 hours ago
    Down 3% about 14 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    AKBA Chart by TradingView
    Basic chart:

    Profile

    Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is AKB-6548, a HIF-PH inhibitor, which is in Phase IIb clinical trials for patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. The company is also developing a development program for patients dependent on dialysis. Akebia Therapeutics, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Biology Kidney Disease Dialysis Anemia Chronic Kidney Disease Kidney Hypoxia Inducible Factors

    Is AKBA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 8 Akebia Q1 2024 Earnings Preview
    May 2 Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
    Apr 28 When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
    Apr 4 Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management
    Apr 2 Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Apr 2 Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)
    Mar 28 FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia
    Mar 28 Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
    Mar 28 Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
    Mar 28 Akebia stock jumps as FDA clears renal anemia therapy
    See more AKBA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.48
    52 Week Low 0.7801
    Average Volume 5,637,785
    200-Day Moving Average 1.33
    50-Day Moving Average 1.56
    20-Day Moving Average 1.37
    10-Day Moving Average 1.35
    Average True Range 0.11
    RSI (14) 47.64
    ADX 18.52
    +DI 23.43
    -DI 23.13
    Chandelier Exit (Long, 3 ATRs) 1.28
    Chandelier Exit (Short, 3 ATRs) 1.55
    Upper Bollinger Bands 1.51
    Lower Bollinger Band 1.24
    Percent B (%b) 0.6
    BandWidth 19.63
    MACD Line -0.05
    MACD Signal Line -0.07
    MACD Histogram 0.0193
    Fundamentals Value
    Market Cap 263.74 Million
    Num Shares 188 Million
    EPS -0.31
    Price-to-Earnings (P/E) Ratio -4.52
    Price-to-Sales 1.61
    Price-to-Book 4.12
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.52
    Resistance 3 (R3) 1.51 1.46 1.50
    Resistance 2 (R2) 1.46 1.43 1.47 1.49
    Resistance 1 (R1) 1.43 1.41 1.45 1.44 1.49
    Pivot Point 1.38 1.38 1.39 1.39 1.38
    Support 1 (S1) 1.35 1.35 1.37 1.36 1.31
    Support 2 (S2) 1.30 1.33 1.31 1.31
    Support 3 (S3) 1.27 1.30 1.30
    Support 4 (S4) 1.28